Regulus Therapeutics (RGLS) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Check Point Software Technology (CHKP) Reports In-Line Q3 EPS
- Silvaco Group Inc (SVCO) PT Lowered to $11 at B.Riley
- B.Riley Reiterates Buy Rating on Celsius Holdings (CELH) ahead of earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
